Jpmorgan Chase & CO Invitae Corp Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.42 - $0.72 $7,274 - $12,470	17,320 Added 1.04%	1,690,275 $1.06 Million
Q3 2023 Nov 14, 2023	SELL	$0.6 - $1.53 $77,466 - $197,538	-129,110 Reduced 7.16%	1,672,955 $1 Million
Q2 2023 Aug 11, 2023	SELL	$1.05 - $1.63 $141,888 - $220,265	-135,132 Reduced 6.98%	1,802,065 $2.04 Million
Q1 2023 May 18, 2023	BUY	$1.2 - $2.73 $358,358 - $815,265	298,632 Added 18.23%	1,937,197 $2.62 Million
Q1 2023 May 11, 2023	SELL	$1.2 - $2.73 $308,682 - $702,251	-257,235 Reduced 13.57%	1,638,565 $2.21 Million

Q4 2022 Feb 13, 2023	BUY	$1.71 - $3.61 $52,050 - $109,884	30,439 Added 1.63%	1,895,800 $3.53 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $8.63 $806,358 - $3.66 Million	424,399 Added 29.45%	1,865,361 $4.59 Million
Q2 2022 Aug 11, 2022	BUY	$2.13 - $9.01 $316,620 - $1.34 Million	148,648 Added 11.5%	1,440,962 $3.52 Million
Q1 2022 May 11, 2022	SELL	$6.28 - $15.59 $1.18 Million - $2.94 Million	-188,368 Reduced 12.72%	1,292,314 $10.3 Million
Q4 2021 Feb 10, 2022	BUY	$14.7 - $28.67 $6.24 Million - $12.2 Million	424,714 Added 40.22%	1,480,682 $22.6 Million
Q3 2021 Nov 12, 2021	BUY	$24.31 - $33.6 $25.7 Million - $35.5 Million	1,055,968 New	1,055,968 $30 Million

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.